Therapeutics

Pain management interviews with Centrexion Therapeutics and Zoetis released ahead of Pain Therapeutics 2017

14 March 2017 | By SMi Group

SMi Group have released a series of interviews ahead of the industry gathering on pain management, Pain Therapeutics 2017.

Assessing neurological ion channel therapeutic and liability targets

10 March 2017 | By Charles River

This webinar explores neurological ion channel therapeutic and liability targets, featuring four subtypes of NMDA receptors. We also discuss the rationale and options for assessment of therapeutic compounds on panels of CNS ion channels for evaluating their risk for CNS liabilities...

Developability assessment of therapeutic antibodies

8 March 2017 | By David Matthews (MRC Technology), Lone Friis (MRC Technology)

Developability assessment is a broad term covering the evaluation of potential therapeutic candidates’ drug-like properties, manufacturability and safety profile. It is important to carry out this assessment as early as possible in the pre-clinical stage development to select the candidate with the most stable profile. This can minimise the risks…

£100 million for Cancer Research’s ‘grand challenge’ competition winners

10 February 2017 | By Niamh Marriott (Drug Target Review)

Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Orexin as a potential drug for treating septic shock

9 February 2017 | By Niamh Marriott (Drug Target Review)

Recent findings by Japanese scientists may be a breakthrough in developing a silver bullet for the treatment of septic shock.

Oncolytic Virotherapy Europe Congress returns to London

2 February 2017 | By KCC Events

The Oncolytic Virotherapy Europe Congress is the only conference in Europe dedicated specifically to the Oncolytic Virotherapy and converting research into the next generation of clinically-relevant virotherapeutics.

StemTek and tebu-bio announce European partnership for Cell2Sphere

19 January 2017 | By Niamh Marriott (Drug Target Review)

Cell2Sphere is the first simple 3D tissue culture kit for labs interested in more accurate, scalable and dynamic experimental research.

Application Note: An Easy-to-Use Assay to Measure Target Cell Death by Antibody Dependent Cellular Phagocytosis (ADCP)

16 January 2017 | By DiscoverX Corporation

With an increasing industry focus on antibody drugs, there is an ever greater need for functional bioassays that interrogate the various mechanisms of action (MOA) for the therapeutic antibody...

Kymab receives $9m R+D grant from Bill & Melinda Gates Foundation

9 January 2017 | By Niamh Marriott (Drug Target Review)

The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.

Nanohyperthermia softens tumours to improve treatment

3 January 2017 | By Niamh Marriott (Drug Target Review)

The mechanical resistance of tumours and collateral damage of standard treatments often hinder efforts to defeat cancers.

Molecular Devices

Practical application of in vivo optical imaging in biotherapeutic biodistribution analyses

14 September 2016 | By Dr Norman Peterson (MedImmune/AstraZeneca)

As advances in protein engineering technology have led to the production of novel and more structurally complex biopharmaceuticals, the ability of these drugs to smoothly traverse the body and arrive at their intended target site has become more unpredictable...

A*STAR and MSD team up to advance peptide therapeutics

19 July 2016 | By Niamh Louise Marriott

A*STAR and MSD have formed a two year collaboration aimed at improving cellular delivery of macrocyclic peptides...

Mechanism-informed phenotypic screening – the missing link for cancer drug discovery?

8 June 2016 | By David S. Bailey (IOTA Pharmaceuticals), Sheraz Gul (Fraunhofer-IME SP)

Cancer cells exhibit huge phenotypic diversity, with many well-defined phenotypes, such as invasion, deregulated proliferation and immune evasion, contributing to disease outcomes, making them uniquely amenable to phenotypic screening1...

Pain therapeutics: New interview released with the Centre for Human Drug Research (CHDR)

14 April 2016 | By SMi Group

SMi’s 16th annual Pain Therapeutics conference returns to London this May and is thrilled to have Dr Geert Jan Groeneveld, Research Director from the Centre for Human Drug Research, as one of the featured speakers for 2016...